ArticleAntiviral research2023
Antiviral activities of two nucleos(t)ide analogs against vaccinia, mpox, and cowpox viruses in primary human fibroblasts.
Article in Antiviral research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 20 citations in OpenAlex.
- Discovery of the nucleoside analogue FMAU as a broad-spectrum anti-orthopoxvirus inhibitor in vitro and in vivo using a structure-guided hit expansion strategy.Emerging microbes & infections · 2026Article
- Design, synthesis and antiviral activity of ciclopirox (CPX) analogs against orthopoxvirus.Bioorganic & medicinal chemistry · 2026Article
- The next generation of orthopoxvirus antivirals: preparing for future threats.Future medicinal chemistry · 2026Article
- Discovery and characterization of a hydroxypyridone-3-carboxamide analog as an antiviral lead against orthopoxviruses.Antimicrobial agents and chemotherapy · 2026Article
- MMF inhibits poxvirus infection by disrupting IMPDH2 interaction with USP5 and inducing its rod-and-ring assemblies.Virologica Sinica · 2026Article
- 3-Hydroxypyrimidine-2,4-dione derivatives as monkeypox virus resolvase (Mpr) inhibitors.RSC medicinal chemistry · 2026Article
- Patient with longstanding mpox keratitis successfully treated with topical Cidofovir 0.5% eye drops: a case report.BMC ophthalmology · 2026Article
- 1-Hydroxy-1,8-napthyridinone (DHN) Analogs Potently Inhibit Monkeypox Virus Resolvase (Mpr).Journal of medicinal chemistry · 2026Article
- Research Review on Inhibitors of Lumpy Skin Disease Virus: From Biological Characteristics, Drug Repurposing, to Computer-Aided Drug Design.International journal of microbiology · 2026Review
- Discovery and Characterization of a Hydroxypyridone-3-carboxamide Analog as an Antiviral Lead against Orthopoxviruses.bioRxiv : the preprint server for biology · 2025Article
- Ciclopirox suppresses poxvirus replication by targeting iron metabolism.Antiviral research · 2025Article
- Ibrutinib inhibits the replication of multiple poxviruses by targeting the Bruton tyrosine kinase.Journal of virology · 2025Article
- Meeting report: 38th international conference on antiviral research in Las Vegas, United States of America, March 17-21, 2025.Antiviral research · 2025Article
- Viral Reprogramming of Nucleotide Synthesis and Its Impact on Viral Infection.Journal of medical virology · 2025Review
- Suppression of poxvirus replication by SC144.Antiviral research · 2025Article
- Discovery of Small-Molecule Orthopoxvirus Resolvase Inhibitors with Antiviral Activity.Journal of medicinal chemistry · 2025Article
- Temporal expression classes and functions of vaccinia virus and mpox (monkeypox) virus genes.mBio · 2025Review
- Computational investigation of antiviral peptide interactions with Mpox DNA polymerase.In silico pharmacology · 2025Article
- FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry.Frontiers in pharmacology · 2025Article
- Recombinant chimeric horsepox virus (TNX-801) is attenuated relative to vaccinia virus strains in bothmSphere · 2024Article
Corrections and comments
- Update of
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Many poxviruses are significant human and animal pathogens, including viruses that cause smallpox and mpox (formerly monkeypox). Identifying novel and potent antiviral compounds is critical to successful drug development targeting poxviruses. Here we tested two compounds, nucleoside trifluridine, and nucleotide adefovir dipivoxil, for antiviral activities against vaccinia virus (VACV), mpox virus (MPXV), and cowpox virus (CPXV) in physiologically relevant primary human fibroblasts. Both compounds potently inhibited the replication of VACV, CPXV, and MPXV (MA001 2022 isolate) in plaque assays. In our recently developed assay based on a recombinant VACV expressing secreted Gaussia luciferase, they both exhibited high potency in inhibiting VACV replication with EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.